X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (33774) 33774
Book Review (10014) 10014
Publication (3703) 3703
Book Chapter (284) 284
Newspaper Article (254) 254
Newsletter (231) 231
Book / eBook (172) 172
Conference Proceeding (94) 94
Dissertation (24) 24
Transcript (10) 10
Magazine Article (9) 9
Reference (6) 6
Trade Publication Article (5) 5
Data Set (4) 4
Web Resource (2) 2
Paper (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (29196) 29196
humans (22042) 22042
animals (15938) 15938
cancer (8169) 8169
oncology (7892) 7892
pharmacology & pharmacy (7168) 7168
male (7113) 7113
mice (6940) 6940
proteins (6828) 6828
female (6375) 6375
apoptosis (5047) 5047
kinases (4558) 4558
cell line, tumor (4536) 4536
research (4351) 4351
biochemistry & molecular biology (4183) 4183
analysis (3920) 3920
rats (3857) 3857
antineoplastic agents - pharmacology (3517) 3517
cell biology (3508) 3508
care and treatment (3450) 3450
health aspects (3366) 3366
expression (3195) 3195
phosphorylation (3145) 3145
signal transduction (3083) 3083
article (3040) 3040
tumors (2918) 2918
antineoplastic agents - therapeutic use (2915) 2915
chemotherapy (2871) 2871
protein kinase inhibitors - pharmacology (2847) 2847
signal transduction - drug effects (2769) 2769
gene expression (2663) 2663
apoptosis - drug effects (2659) 2659
activation (2596) 2596
dose-response relationship, drug (2596) 2596
medicine (2583) 2583
middle aged (2573) 2573
research article (2534) 2534
physiological aspects (2501) 2501
protein kinase inhibitors - therapeutic use (2418) 2418
in-vitro (2410) 2410
neoplasms - drug therapy (2379) 2379
multidisciplinary sciences (2374) 2374
chemistry, medicinal (2353) 2353
pharmacology (2321) 2321
rodents (2284) 2284
adult (2268) 2268
drug therapy (2259) 2259
cells (2232) 2232
mutation (2231) 2231
cell proliferation - drug effects (2210) 2210
aged (2167) 2167
pharmacokinetics (2126) 2126
inhibition (2124) 2124
in-vivo (2060) 2060
medicine & public health (2012) 2012
neurosciences (1931) 1931
inflammation (1904) 1904
genetic aspects (1885) 1885
science (1863) 1863
cancer therapies (1823) 1823
biology (1821) 1821
review (1809) 1809
inhibitors (1774) 1774
treatment outcome (1768) 1768
therapy (1755) 1755
clinical trials (1748) 1748
oxidative stress (1696) 1696
metastasis (1695) 1695
studies (1688) 1688
cells, cultured (1669) 1669
protein binding (1655) 1655
metabolism (1646) 1646
disease models, animal (1635) 1635
drugs (1632) 1632
medical research (1632) 1632
tyrosine (1574) 1574
pharmacology/toxicology (1569) 1569
breast cancer (1556) 1556
hematology (1554) 1554
cell cycle (1544) 1544
physiology (1528) 1528
enzymes (1516) 1516
medicine, research & experimental (1502) 1502
enzyme inhibitors - pharmacology (1490) 1490
angiogenesis (1472) 1472
protein kinase inhibitors - pharmacokinetics (1471) 1471
structure-activity relationship (1470) 1470
drug discovery (1461) 1461
drug design (1455) 1455
protein (1450) 1450
xenograft model antitumor assays (1447) 1447
rats, sprague-dawley (1437) 1437
cell line (1434) 1434
biochemistry (1403) 1403
toxicity (1343) 1343
growth (1331) 1331
protein kinases (1328) 1328
antineoplastic agents - pharmacokinetics (1322) 1322
cell survival - drug effects (1318) 1318
antineoplastic agents (1301) 1301
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (104) 104
Collection Dvlpm't (Acquisitions) - Vendor file (13) 13
UofT at Mississauga - Stacks (9) 9
Online Resources - Online (7) 7
UofT at Scarborough - Stacks (7) 7
Engineering & Comp. Sci. - Stacks (6) 6
Collection Dvlpm't (Acquisitions) - Closed Orders (5) 5
Chemistry (A D Allen) - Stacks (3) 3
UTL at Downsview - May be requested (2) 2
Collection Dvlpm't (Acquisitions) - Cancelled Order (1) 1
Earth Sciences (Noranda) - Stacks (1) 1
Engineering & Comp. Sci. - Reference (1) 1
Gerstein Science - Circulation Desk (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
UofT at Mississauga - Missing (1) 1
UofT at Mississauga - Reference (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (34580) 34580
German (28) 28
Spanish (24) 24
French (21) 21
Japanese (9) 9
Chinese (6) 6
Russian (5) 5
Czech (3) 3
Danish (3) 3
Arabic (1) 1
Dutch (1) 1
Italian (1) 1
Polish (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Pharmacokinetics, ISSN 0312-5963, 9/2011, Volume 50, Issue 9, pp. 551 - 603
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2015, Volume 372, Issue 18, pp. 1689 - 1699
AZD9291, an irreversible inhibitor of epidermal growth factor receptor, was associated with tumor responses in the majority of patients with advanced... 
MEDICINE, GENERAL & INTERNAL | GEFITINIB | PLACEBO | PHASE-III | ACQUIRED-RESISTANCE | OPEN-LABEL | MUTATIONS | AFATINIB | IRREVERSIBLE EGFR | CHEMOTHERAPY | ERLOTINIB | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Acrylamides - pharmacokinetics | Dose-Response Relationship, Drug | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Aniline Compounds - administration & dosage | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - genetics | Aniline Compounds - pharmacokinetics | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Acrylamides - administration & dosage | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Aniline Compounds - adverse effects | Acrylamides - adverse effects | Clinical trials | Care and treatment | Usage | Diagnosis | Lung cancer, Non-small cell | Patient outcomes | Tyrosine | Appetite | Inhibitor drugs | Epidermal growth factor receptors | Lung | Lung cancer | Diarrhea | Nausea | Drug resistance | Kinases | Patients | Epidermal growth factor | Pharmacokinetics | Protein-tyrosine kinase | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2016, Volume 374, Issue 4, pp. 323 - 332
Acalabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase with greater specificity for the enzyme than the first-in-class agent, ibrutinib. It had... 
B-CELL RECEPTOR | MEDICINE, GENERAL & INTERNAL | ACTIVATION | IN-VIVO | X-LINKED AGAMMAGLOBULINEMIA | IBRUTINIB | BTK | PCI-32765 | TYROSINE KINASE INHIBITOR | LYMPHOMA | OPEN-LABEL | Recurrence | Benzamides - pharmacokinetics | Humans | Middle Aged | Pyrazines - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Protein Kinase Inhibitors - adverse effects | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Benzamides - administration & dosage | Antineoplastic Agents - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Benzamides - adverse effects | Headache - chemically induced | Chromosome Deletion | Protein Kinase Inhibitors - pharmacokinetics | Administration, Oral | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Agammaglobulinaemia Tyrosine Kinase | Pyrazines - pharmacokinetics | Pyrazines - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Treatment outcome | Usage | Care and treatment | Safety and security measures | Lymphocytic leukemia | Analysis | Clinical trials | Pharmacology | Dosage and administration | Pharmacokinetics | Antineoplastic agents | Tyrosine | Headache | Pharmacodynamics | Transformation | Chronic lymphatic leukemia | Inhibitor drugs | Leukemia | Diarrhea | Chromosome deletion | Lymphatic leukemia | Kinases | Lymphoma | Bruton's tyrosine kinase | Patients | Clonal deletion | Lymphomas | Safety | Drug therapy | Lymphocytosis | Protein-tyrosine kinase | Chromosome 17 | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 8, pp. 773 - 781
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2017, Volume 376, Issue 18, pp. 1723 - 1736
Journal Article
Nature Chemical Biology, ISSN 1552-4450, 07/2015, Volume 11, Issue 7, pp. 525 - 531
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2014, Volume 370, Issue 13, pp. 1189 - 1197
Ceritinib is 20 times as potent as crizotinib at inhibiting anaplastic lymphoma kinase (ALK) in vitro. In patients, ceritinib produced antitumor responses in... 
TRIALS | MEDICINE, GENERAL & INTERNAL | GEFITINIB | EML4-ALK FUSION GENE | MUTATION | ACQUIRED-RESISTANCE | CRIZOTINIB | CLINICAL RESISTANCE | KINASE INHIBITOR | STI-571 | EGFR | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Sulfones - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Young Adult | Recombination, Genetic | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - genetics | Pyrimidines - administration & dosage | Treatment Outcome | Sulfones - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - mortality | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Maximum Tolerated Dose | Receptor Protein-Tyrosine Kinases - genetics | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Sulfones - administration & dosage | Antimitotic agents | Care and treatment | Dosage and administration | Research | Lung cancer, Non-small cell | Antineoplastic agents | Lung cancer | Diarrhea | Insulin-like growth factors | Dehydration | Kinases | Patients | Lymphoma | Gene amplification | Vomiting | Gene rearrangement | Hypophosphatemia | Antitumor activity | Mutation | Pharmaceutical industry | Protein-tyrosine kinase | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2015, Volume 372, Issue 18, pp. 1700 - 1709
Patients with non–small-cell lung cancer and mutated epidermal growth factor receptors who develop resistance to EGFR inhibitors through a particular mutation... 
TYROSINE KINASE INHIBITORS | MEDICINE, GENERAL & INTERNAL | PHASE-II TRIAL | GEFITINIB | ADENOCARCINOMA | ACQUIRED-RESISTANCE | MUTATIONS | AFATINIB | ERLOTINIB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Acrylamides - pharmacokinetics | Dose-Response Relationship, Drug | Hyperglycemia - chemically induced | Antineoplastic Agents - adverse effects | Female | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - genetics | Pyrimidines - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Acrylamides - administration & dosage | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Acrylamides - adverse effects | Clinical trials | Care and treatment | Usage | Diagnosis | Lung cancer, Non-small cell | Hyperglycemia | Chemotherapy | Epidermal growth factor | Inhibitor drugs | Epidermal growth factor receptors | Lung cancer | Genes | Antitumor activity | Pharmacokinetics | Patients | Index Medicus | Abridged Index Medicus
Journal Article